Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-27T02:26:26.073Z Has data issue: false hasContentIssue false

15 - Amyloid Imaging

Published online by Cambridge University Press:  22 November 2017

Heather Jacene
Affiliation:
Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Hossein Jadvar
Affiliation:
University of Southern California Keck School of Medicine, Los Angeles
Heather Jacene
Affiliation:
Dana-Farber Cancer Institute, Boston
Michael Graham
Affiliation:
University of Iowa
Get access

Summary

Introduction

Amyloid is protein composed of linear nonbranching fibrils arranged in sheets. Amyloidosis is a disease characterized by misfolding proteins, aggregation, and extracellular depositions of amyloid in tissue and organs. There are at least 20 described types of amyloid protein in humans which vary by precursor protein and resultant organs of deposition. Amyloid deposition may be localized (e.g. brain in Alzheimer's disease (AD)) or systemic (e.g. primary light chain amyloidosis), and there is a wide range of clinical manifestations, from none to severe organ dysfunction.

In regard to selective imaging of amyloid protein, most work thus far has been on developing agents targeting beta (β)-amyloid (Aβ) plaques in the brain, which will be the focus of this chapter. Clinical applications for amyloid imaging of the heart and systemic amyloid deposition are also emerging.

Beta Amyloid Plaques and Pathologic Basis for Alzheimer's Disease

Aβ protein is a 36–43 amino acid peptide cleaved from the transmembrane Aβ protein precursor by β and gamma (γ) sectretase (Figure 15.1). The normal function of Aβ protein is not well understood. Some described potential roles are activation of kinase enzymes, protection against oxidative stress, regulation of cholesterol transport, and serving as a transcription factor or antimicrobial. Plaques containing Aβ protein are described as diffuse or dense, with current imaging probes having affinity for the latter.

Radiopharmaceuticals for Aβ Amyloid PET Imaging

Carbon-11 Pittsburgh Complex B

Carbon-11 Pittsburgh (11C-PiB) was the first radiopharmaceutical developed for targeting Aβ plaques. 11C-PiB is derived from thioflavin T, a fluorescent dye that binds amyloid and is used to histologically identify plaques in brain tissue specimens. PET imaging is performed 40–50 minutes after tracer injection for 20–30 minutes. Normal distribution of 11C-PiB is in cerebral white matter (Figure 15.2, top row). In disease states, there is usually much less dense plaque deposition in cerebellar gray matter compared to cortical gray matter, so the cerebellum is most commonly used as a reference region. Visually, uptake of 11C-PiB in cortical gray matter at least equal to or greater than white matter is considered abnormal (Figure 15.2, bottom row). Standardized uptake value (SUV) ratios comparing cortical to cerebellar gray matter uptake may also be determined, with the upper limit of normal reported as 1.3–1.6. Correlations between 11C-PiB uptake in cortical gray matter and postmortem assessments of Aβ plaques have been demonstrated.

Type
Chapter
Information
Molecular Imaging
An Introduction
, pp. 76 - 80
Publisher: Cambridge University Press
Print publication year: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Antoni, G, Lubberink, M, Estrada, S, Axelsson, J, Carlson, K, Lindsjö, L, Kero, T, Långström, B, Granstam, SO, Rosengren, S, Vedin, O, Wassberg, C, Wikström, G, Westermark, P, Sörensen, J. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54(2):213–20.CrossRefGoogle ScholarPubMed
Chen, W, Dilsizian, V. Molecular imaging of amyloidosis: will the heart be the next target after the brain? Curr Cardiol Rep. 2012;14:226–33.CrossRefGoogle Scholar
Clark, CM, Schneider, JA, Bedell, BJ, Beach, TG, Bilker, WB, Mintun, MA, Pontecorvo, MJ, Hefti, F, Carpenter, AP, Flitter, ML, Krautkramer, MJ, Kung, HF, Coleman, RE, Doraiswamy, PM, Fleisher, AS, Sabbagh, MN, Sadowsky, CH, Reiman, EP, Zehntner, SP, Skovronsky, DM. AV45-A07 study group. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275–83.Google Scholar
Drzezga, A, Grimmer, T, Henriksen, G, Stangier, I, Perneczky, R, Diehl-Schmid, J, Mathis, CA, Klunk, WE, Price, J, DeKosky, S, Wester, HJ, Schwaiger, M, Kurz, A. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage. 2008;39(2):619–33.CrossRefGoogle ScholarPubMed
Johnson, KA, Minoshima, S, Bohnen, NI, Donohoe, KJ, Foster, NL, Herscovitch, P, Karlawish, JH, Rowe, CC, Carrillo, MC, Hartley, DM, Hedrick, S, Pappas, V, Thies, WH. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med. 2013;54(3):476–90.CrossRefGoogle Scholar
Klunk, WE, Engler, H, Nordberg, A, Wang, Y, Blomqvist, G, Holt, DP, Bergström, M, Savitcheva, I, Huang, GF, Estrada, S, Ausén, B, Debnath, ML, Barletta, J, Price, JC, Sandell, J, Lopresti, BJ, Wall, A, Koivisto, P, Antoni, G, Mathis, CA, Långström, B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–19.CrossRefGoogle ScholarPubMed
Okello, A, Koivunen, J, Edison, P, Archer, HA, Turkheimer, FE, Någren, K, Bullock, R, Walker, Z, Kennedy, A, Fox, NC, Rossor, MN, Rinne, JO, Brooks, DJ. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009;73(10):754–60.CrossRefGoogle ScholarPubMed
Rabinovici, GD, Furst, AJ, O'Neil, JP, Racine, CA, Mormino, EC, Baker, SL, Chetty, S, Patel, P, Pagliaro, TA, Klunk, WE, Mathis, CA, Rosen, HJ, Miller, BL, Jagust, WJ. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68(15):1205–12.CrossRefGoogle ScholarPubMed
Rowe, CC, Ng, S, Ackermann, U, Gong, SJ, Pike, K, Savage, G, Cowie, TF, Dickinson, KL, Maruff, P, Darby, D, Smith, C, Woodward, M, Merory, J, Tochon-Danguy, H, O'Keefe, G, Klunk, WE, Mathis, CA, Price, JC, Masters, CL, Villemagne, VL. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718–25.CrossRefGoogle ScholarPubMed
Rowe, CC, Ellis, KA, Rimajova, M, Bourgeat, P, Pike, KE, Jones, G, Fripp, J, Tochon-Danguy, H, Morandeau, L, O'Keefe, G, Price, R, Raniga, P, Robins, P, Acosta, O, Lenzo, N, Szoeke, C, Salvado, O, Head, R, Martins, R, Masters, CL, Ames, D, Villemagne, VL. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275–83.CrossRefGoogle Scholar
Rowe, CC, Villemagne, RL. Brain Amyloid Imaging. J Nucl Med. 2011;52(11):1733–40.Google ScholarPubMed
Svedberg, MM, Hall, H, Hellström-Lindahl, E, Estrada, S, Guan, Z, Nordberg, A, Långström, B. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int. 2009;54(5–6):347–57.CrossRefGoogle ScholarPubMed
Villemagne, VL, Pike, KE, Chételat, G, Ellis, KA, Mulligan, RS, Bourgeat, P, Ackermann, U, Jones, G, Szoeke, C, Salvado, O, Martins, R, O'Keefe, G, Mathis, CA, Klunk, WE, Ames, D, Masters, CL, Rowe, CC. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181–92.CrossRefGoogle ScholarPubMed
Wong, DF, Rosenberg, PB, Zhou, Y, Kumar, A, Raymont, V, Ravert, HT, Dannals, RF, Nandi, A, Brasić, JR, Ye, W, Hilton, J, Lyketsos, C, Kung, HF, Joshi, AD, Skovronsky, DM, Pontecorvo MJ. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913–20.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats No formats are currently available for this content.
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats No formats are currently available for this content.
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats No formats are currently available for this content.
×